Abstract: The present invention relates to a method for increasing the productivity of 2?-fucosyllactose through various changes in culture medium composition and culturing on the basis of lactose, which is a substrate, wherein 2-fucosyllactose can be continuously produced in a high-yield at an optimum lactose concentration discovered by a culturing method of the present invention.

Abstract: The present disclosure relates to a metal material for a container for storing high-purity hydrogen fluoride, and to a manufacturing method therefor. Specifically, the disclosure relates to a metal material for a container for storing high-purity hydrogen fluoride, and a manufacturing method therefor. The metal material includes a graphite layer on the surface of a metal substance, and nickel fluoride films formed in structural defect spaces within the graphite layer, so that corrosion resistance and scratch resistance are improved, and thus high-purity hydrogen fluoride, which is a corrosive gas, can be stored and transferred without being contaminated.

Abstract: Disclosed are a food composition containing 2?-fucosyllactose and a pharmaceutical composition containing 2?-fucosyllactose that are effective in ameliorating, preventing or treating various cerebro-cardiovascular diseases caused by thrombogenesis, and a method for ameliorating a cerebro-cardiovascular disease caused by a thrombus by administering a composition including 2?-fucosyllactose (2?-FL) to a subject in need thereof. The 2?-fucosyllactose (2?-FL) exhibits antagonistic (inhibitory) activity against CRP and collagen, which are agonists of platelets, and thus can be used to inhibit thrombogenesis due to abnormal platelet activity.

Abstract: Disclosed is a method for improving the productivity of 2?-fucosyllactose (2?-FL) through enzymatic treatment. Lactose used as a substrate in the stationary phase during culture is degraded by treatment with a small amount of enzyme, the resulting glucose is consumed to produce guanosine diphosphate-L-fucose as a precursor of 2?-fucosyllactose, and the use of lactose left after culture can be maximally utilized for the production of 2?-fucosyllactose. As a result, it is possible to increase the productivity of 2?-fucosyllactose in an economically efficient manner because additional glucose is not required while minimizing by-products.

Abstract: Disclosed is a method for improving the productivity of 2?-fucosyllactose (2?-FL) through enzymatic treatment. Lactose used as a substrate in the stationary phase during culture is degraded by treatment with a small amount of enzyme, the resulting glucose is consumed to produce guanosine diphosphate-L-fucose as a precursor of 2?-fucosyllactose, and the use of lactose left after culture can be maximally utilized for the production of 2?-fucosyllactose. As a result, it is possible to increase the productivity of 2?-fucosyllactose in an economically efficient manner because additional glucose is not required while minimizing by-products.

Abstract: Disclosed is a method for preventing or treating muscular atrophy or sarcopenia, the method comprising administering a composition comprising 2?-fucosyllactose (2?-FL) as an active ingredient to a subject in need thereof. The composition administered to the subject increases the expression of genes related to mitochondrial function enhancement and mitochondrial biosynthesis, and reduces the expression of atrogin-1 and MuRF1 genes, which are markers for muscular atrophy, thereby providing effects of strengthening muscles and preventing muscular atrophy or sarcopenia.

Abstract: Disclosed are a food composition containing 2?-fucosyllactose and a pharmaceutical composition containing 2?-fucosyllactose that are effective in ameliorating, preventing or treating various cerebrovascular diseases caused by thrombogenesis, and a method for ameliorating a cerebrovascular disease caused by a thrombus by administering a composition including 2?-fucosyllactose (2?-FL) to a subject in need thereof. The 2?-fucosyllactose (2?-FL) exhibits antagonistic (inhibitory) activity against CRP and collagen, which are agonists of platelets, and thus can be used to inhibit thrombogenesis due to abnormal platelet activity.

Abstract: Disclosed is fucosyllactose having antiviral activity and inhibitory activity against viral infection, and a method for preventing or treating a viral infection by administering a composition including fucosyllactose as an active ingredient to a subject in need thereof. It was found that 2?-fucosyllactose and 3-fucosyllactose, which are human milk oligosaccharides (HMOs), have antiviral activity, and in particular, 3-fucosyllactose in vitro and in vivo exhibits much higher antiviral activity and inhibitory activity against viral infection compared to 2?-fucosyllactose and is thus useful as an antiviral agent.

Abstract: Disclosed is a method for producing 2?-fucosyllactose from a recombinant Corynebacterium sp. introduced with fucosyltransferase derived from Pseudopedobacter saltans. The recombinant Corynebacterium sp. microorganism introduced with fucosyltransferase derived from Pseudopedobacter saltans is capable of producing 2?-fucosyllactose at a high concentration, high yield and high productivity.

Abstract: Disclosed is a food or pharmaceutical composition containing 2?-fucosyllactose (2?-FL) for preventing a stroke. The food or pharmaceutical composition containing 2?-fucosyllactose (2?-FL) is highly effective in preventing a stroke.

Abstract: Disclosed is a method for producing 2?-fucosyllactose from a recombinant Corynebacterium sp. introduced with fucosyltransferase derived from Pseudopedobacter saltans. The recombinant Corynebacterium sp. microorganism introduced with fucosyltransferase derived from Pseudopedobacter saltans is capable of producing 2?-fucosyllactose at a high concentration, high yield and high productivity.

Abstract: An apparatus for producing disilane through pyrolysis of monosilane, includes: a monosilane pyrolysis unit; a solid particle removal unit which removes solid particles generated in the pyrolysis unit; a condensing unit which liquefies and collects unreacted monosilane, and disilane and higher silanes with three (3) to seven (7) silicon atoms as pyrolysis products excluding hydrogen from a gas with the solid particles removed; a first separation unit which separates monosilane from a mixture of the liquefied unreacted monosilane, disilane and higher silanes; and a second separation unit which separates disilane and higher silanes from the mixture with the monosilane removed. In accordance with the present disclosure, disilane can be produced economically and efficiently with high purity through pyrolysis of monosilane.

Abstract: An apparatus for producing disilane through pyrolysis of monosilane, includes: a monosilane pyrolysis unit; a solid particle removal unit which removes solid particles generated in the pyrolysis unit; a condensing unit which liquefies and collects unreacted monosilane, and disilane and higher silanes with three (3) to seven (7) silicon atoms as pyrolysis products excluding hydrogen from a gas with the solid particles removed; a first separation unit which separates monosilane from a mixture of the liquefied unreacted monosilane, disilane and higher silanes; and a second separation unit which separates disilane and higher silanes from the mixture with the monosilane removed. In accordance with the present disclosure, disilane can be produced economically and efficiently with high purity through pyrolysis of monosilane.